While rare in most cancers, these fusions indicate poor prognosis and are candidates for FDA-approved FGFR-targeted therapies, including infigratinib, pemigratinib and futibatinib for cholangiocarcinoma with FGFR2 fusions and erdaftinib for urothelial cancers with FGFR3 fusions [66]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.